Therefore, peripheral targeting of CB1 by AM6545 and AM4113 is a promising therapeutic strategy in BPH treatment without the side effects associated with rimonabant that stems from the central CB1 blockade [19]. This evidence concerns the gene CNR1 and benign prostatic hyperplasia.